Literature DB >> 1533898

Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor.

G Sarmay1, J Lund, Z Rozsnyay, J Gergely, R Jefferis.   

Abstract

In the present study 3-iodo-4-hydroxy-5-nitrophenacetyl (NIP)-specific antibodies were compared for induction of antibody dependent lysis of NIP-derivatised red blood cells effected by pre-stimulated U937 or HL-60 cells and by K cells. The chimaeric antibodies have heavy chains corresponding to human IgG subclasses 1-4, and include site-directed mutants of IgG3 as well as the aglycosylated form of IgG3; a mouse IgG2b antibody and a site-directed mutant IgG2b were also examined. rIFN stimulated U937 or HL-60 cells express increased levels of Fc gamma R1 compared to unstimulated cells; PMA stimulated HL-60 and U937 cells express an increased level of Fc gamma R11 compared to unstimulated cells; K cells express Fc gamma R111. Using these effector cell populations and the target cells mentioned above, we have compared anti-NIP antibodies with different heavy chain constant domains for their ability to induce ADCC through human Fc gamma R1, Fc gamma R11 and Fc gamma R111. The results suggest that all three human Fc gamma receptors appear to recognise a binding site on IgG within the lower hinge (residues 234-237) and trigger ADCC via this site, but that each receptor sees this common site in a different way. The possibility that other amino acid residues also participate in the binding/triggering site(s) cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1533898     DOI: 10.1016/0161-5890(92)90200-h

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  29 in total

1.  Sequence similarities of protein kinase peptide substrates and inhibitors: comparison of their primary structures with immunoglobulin repeats.

Authors:  J Kubrycht; J Borecký; K Sigler
Journal:  Folia Microbiol (Praha)       Date:  2002       Impact factor: 2.099

2.  The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity.

Authors:  JianMin Lin; Jared L Spidel; Christopher J Maddage; Katherine A Rybinski; Rina P Kennedy; Candice L M Krauthauser; Young Chul Park; Earl F Albone; Sara Jacob; Matthew T Goserud; Bryon P Martinez; Qimin Chao; Yuhong Zhou; Nicholas C Nicolaides; J Bradford Kline; Luigi Grasso
Journal:  Cancer Biol Ther       Date:  2013-08-28       Impact factor: 4.742

3.  Engineered antibody Fc variants with enhanced effector function.

Authors:  Greg A Lazar; Wei Dang; Sher Karki; Omid Vafa; Judy S Peng; Linus Hyun; Cheryl Chan; Helen S Chung; Araz Eivazi; Sean C Yoder; Jost Vielmetter; David F Carmichael; Robert J Hayes; Bassil I Dahiyat
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-06       Impact factor: 11.205

4.  Immunoglobulin subclass determines ability of immunoglobulin (Ig)G to capture and activate neutrophils presented as normal human IgG or disease-associated anti-neutrophil cytoplasm antibody (ANCA)-IgG.

Authors:  T Pankhurst; G Nash; J Williams; R Colman; A Hussain; C Savage
Journal:  Clin Exp Immunol       Date:  2011-03-10       Impact factor: 4.330

5.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

Review 6.  Functional diversification of IgGs through Fc glycosylation.

Authors:  Taia T Wang; Jeffrey V Ravetch
Journal:  J Clin Invest       Date:  2019-09-03       Impact factor: 14.808

7.  The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.

Authors:  A Morgan; N D Jones; A M Nesbitt; L Chaplin; M W Bodmer; J S Emtage
Journal:  Immunology       Date:  1995-10       Impact factor: 7.397

Review 8.  Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics.

Authors:  Daniela Bumbaca; C Andrew Boswell; Paul J Fielder; Leslie A Khawli
Journal:  AAPS J       Date:  2012-05-18       Impact factor: 4.009

9.  A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.

Authors:  Brian Moldt; Mami Shibata-Koyama; Eva G Rakasz; Niccole Schultz; Yutaka Kanda; D Cameron Dunlop; Samantha L Finstad; Chenggang Jin; Gary Landucci; Michael D Alpert; Anne-Sophie Dugast; Paul W H I Parren; Falk Nimmerjahn; David T Evans; Galit Alter; Donald N Forthal; Jörn E Schmitz; Shigeru Iida; Pascal Poignard; David I Watkins; Ann J Hessell; Dennis R Burton
Journal:  J Virol       Date:  2012-03-28       Impact factor: 5.103

10.  Soluble FcgammaRIIa inhibits rheumatoid factor binding to immune complexes.

Authors:  Bruce D Wines; Amanda Gavin; Maree S Powell; Michael Steinitz; Russell R C Buchanan; P Mark Hogarth
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.